Novartis kidney cancer drug clears key hurdle

Everolimus (RAD001) significantly extends progression-free survival in advanced kidney cancer patients after failure of other targeted therapy  Outstanding interim results cause independent data monitoring committee to immediately share findings; patients on placebo to be offered everolimus  Everolimus (RAD001) tablet, taken once daily, demonstrated highly effective anti-tumor activity through continuous targeted inhibition of mTOR  Results of RECORD-1 trial address unmet medical need in renal cell cancer with worldwide regulatory filings planned for second half of 2008  Complete results to be submitted as late-breaking abstract for presentation at the American Society of Clinical Oncology meeting  Basel, February 28, 2008 — An independent data monitoring committee stopped a major Phase III clinical trial of the investigational drug everolimus (RAD001) today after interim results showed significantly better progression-free survival in patients with advanced kidney cancer who received everolimus compared to placebo. The committee stopped the trial of more than 400 patients conducted in 12 countries because the study met its primary endpoint. The interim findings are being shared with investigators to allow them to offer everolimus to patients remaining on placebo.  Everolimus may fulfill an unmet medical need for patients with advanced renal cell cancer (RCC) who currently have no approved treatment options.   E...
Source: Kidney Cancer Association - Category: Urology & Nephrology Source Type: news

Related Links:

Authors: Karczewski J, Śledzińska E, Baturo A, Jończyk I, Maleszko A, Maleszko A, Samborski P, Begier-Krasińska B, Dobrowolska A Abstract The prevalence of obesity has recently increased dramatically and has contributed to the increasing prevalence of various pathological conditions, including type 2 diabetes mellitus, nonalcoholic fatty liver disease, asthma, various types of cancer, cardiovascular and neurodegenerative diseases, and others. Accumulating evidence points to localized inflammation in adipose tissue, which, in turn, promotes systemic low-grade inflammation as a primary force contributing to the d...
Source: European Cytokine Network - Category: Molecular Biology Tags: Eur Cytokine Netw Source Type: research
Publication date: 15 December 2018Source: New Scientist, Volume 240, Issue 3208Author(s):
Source: New Scientist - Category: Science Source Type: research
DiscussionOur analysis presents the first transmission modelling of cohort data for RSV and we find that it is important to consider the household social structuring and household size when modelling transmission. The increased infectiousness of symptomatic individuals implies that a vaccine against RSV related disease would also have an impact on infection transmission. Together, the weak cross immunity between RSV groups and the possibility of different transmission niches could form part of the explanation for the group co-existence.Graphical Abstract
Source: Epidemics - Category: Epidemiology Source Type: research
CONCLUSION: Bone pain is a common and sometimes severe symptom of bone metastases in advanced breast cancer and a common reason for initiating BTA treatment. Safety and efficacy were the main factors considered by physicians when selecting BTAs. Past Presentations: Data previously presented at the ISPOR 18th Annual European Congress, Milan, Italy; November 7-11, 2015 and at the Breast Cancer Symposium, San Francisco, CA, USA; September 25-27, 2015. PMID: 30550358 [PubMed - as supplied by publisher]
Source: Current Medical Research and Opinion - Category: Research Tags: Curr Med Res Opin Source Type: research
This study compared compliance and persistence of everolimus between commercial and Medicaid patients using the US claims data. METHODS: Patients with ≥1 claim of TSC with renal angiomyolipoma or SEGA were selected from the MarketScan commercial (1/1/2009-8/31/2016) and Medicaid (1/1/2009-6/30/2015) databases. Patients were followed from index date (the earliest date of TSC, renal angiomyolipoma, or SEGA diagnosis) to death or end of data. Non-persistence was defined as ≥60-day gap without everolimus and medication possession ratio (MPR) were assessed among the subset of patients with ≥1-year of follow-up from...
Source: Current Medical Research and Opinion - Category: Research Tags: Curr Med Res Opin Source Type: research
CONCLUSIONS: Although the use of PP-CSF is commonplace in current US clinical practice, underutilization in cancer patients receiving chemotherapy regimens with an intermediate/high-risk for FN may still be an issue. Use of same-day PP-CSF increased markedly from the end of 2015, although this finding reflects (at least in part) increased uptake of pegfilgrastim delivered via an on-body injector as well as the recent change in clinical practice guidelines. Overall, patients receiving PP-CSF appear to have a lower risk of FN during the first cycle of chemotherapy. PMID: 30550346 [PubMed - as supplied by publisher]
Source: Current Medical Research and Opinion - Category: Research Tags: Curr Med Res Opin Source Type: research
Publication date: Available online 16 December 2018Source: European UrologyAuthor(s): Anwar R. Padhani, Masoom A. Haider, Arnauld Villers, Jelle O. Barentsz
Source: European Urology - Category: Urology & Nephrology Source Type: research
Publication date: Available online 15 December 2018Source: European UrologyAuthor(s): Yongbao Wei, Tao Li, Longfei Liu
Source: European Urology - Category: Urology & Nephrology Source Type: research
Publication date: Available online 16 December 2018Source: Journal of Minimally Invasive GynecologyAuthor(s): Yoichi Aoki, Hiroyuki Kanao, Iwaho Kikuchi, Hidetaka Nomura, Syuhei Okamoto, Tsuyoshi Hisa, Takeru Sugihara, Rie Kitano, Kohei Omatsu, Terumi Tanigawa, Nobuhiro TakeshimaAbstractStudy ObjectiveTo compare 3 laparoscopic contained morcellation techniques in terms of feasibility and safety.DesignPilot study in an animal model (Canadian Task Force classification II-1).SettingGynecologic oncology department at a cancer institute in Japan.PatientsPorcine Model.InterventionsThree contained morcellation techniques were tes...
Source: Journal of Minimally Invasive Gynecology - Category: OBGYN Source Type: research
Publication date: February 2019Source: Journal of Functional Foods, Volume 53Author(s): Daniela Guardado-Félix, Marilena Antunes-Ricardo, María R. Rocha-Pizaña, Ana-Carolina Martínez-Torres, Janet A. Gutiérrez-Uribe, Sergio O. Serna SaldivarAbstractThe effect of selenium enriched chickpea sprouts with and without isoflavonoids (IS) on colorectal cancer (CRC) tumor growth was evaluated in immune-suppressed mice xenografted. Two levels of selenium (0.17 and 2.29 µg/g) and isoflavonoids (0 and 2.34 mg/g) were evaluated in the diets. High intake of Se (2.29 µg/g) with and wi...
Source: Journal of Functional Foods - Category: Nutrition Source Type: research
More News: Avastin | Cancer | Cancer & Oncology | Cancer Therapy | Cancer Vaccines | Cardiology | Clinical Trials | Government | Health | Heart | Heart Transplant | Kidney Cancer | Kidney Transplant | Kidney Transplantation | Lung Transplant | Lymphoma | Neurology | Oral Cancer | Pfizer | Renal Cell Carcinoma | Skin | Study | Transplant Surgery | Transplants | Tuberous Sclerosis | Urology & Nephrology | Vaccines